08-08-2025
Analysts Offer Insights on Healthcare Companies: EyePoint Pharmaceuticals (EYPT), NewAmsterdam Pharma Company (NAMS) and Surgery Partners (SGRY)
There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on EyePoint Pharmaceuticals (EYPT – Research Report), NewAmsterdam Pharma Company (NAMS – Research Report) and Surgery Partners (SGRY – Research Report) with bullish sentiments.
Elevate Your Investing Strategy:
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
EyePoint Pharmaceuticals (EYPT)
RBC Capital analyst Lisa Walter maintained a Buy rating on EyePoint Pharmaceuticals on August 6 and set a price target of $28.00. The company's shares closed last Thursday at $10.07.
According to Walter is ranked 0 out of 5 stars with an average return of -15.9% and a 47.6% success rate. Walter covers the Healthcare sector, focusing on stocks such as 4D Molecular Therapeutics, Adverum Biotechnologies, and Apellis Pharmaceuticals.
Currently, the analyst consensus on EyePoint Pharmaceuticals is a Strong Buy with an average price target of $26.71, representing a 147.1% upside. In a report issued on July 29, Mizuho Securities also maintained a Buy rating on the stock with a $26.00 price target.
NewAmsterdam Pharma Company (NAMS)
RBC Capital analyst Leonid Timashev maintained a Buy rating on NewAmsterdam Pharma Company on August 6 and set a price target of $39.00. The company's shares closed last Thursday at $22.96.
According to Timashev is a 3-star analyst with an average return of 4.7% and a 44.1% success rate. Timashev covers the Healthcare sector, focusing on stocks such as Perspective Therapeutics, Edgewise Therapeutics, and Jazz Pharmaceuticals.
NewAmsterdam Pharma Company has an analyst consensus of Strong Buy, with a price target consensus of $48.18, a 103.0% upside from current levels. In a report issued on July 30, Cantor Fitzgerald also maintained a Buy rating on the stock with a $42.00 price target.
Surgery Partners (SGRY)
In a report issued on August 6, Ben Hendrix from RBC Capital maintained a Buy rating on Surgery Partners, with a price target of $35.00. The company's shares closed last Thursday at $23.22.
According to Hendrix is a 3-star analyst with an average return of 1.1% and a 48.5% success rate. Hendrix covers the Healthcare sector, focusing on stocks such as Ardent Health Partners, Inc., Aveanna Healthcare Holdings, and Brookdale Senior Living.
Currently, the analyst consensus on Surgery Partners is a Moderate Buy with an average price target of $30.90, which is a 36.5% upside from current levels. In a report issued on August 5, TD Cowen also reiterated a Buy rating on the stock with a $28.00 price target.
